---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Executive summary: Disease burden"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Disease burden. Topics: Summary: definition and prevalence, Summary: natural history and long-term morbidity, and Summary: humanistic and economic burden. 3 evidence topics quoted from 31 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary/disease-burden"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Obstructive sleep apnea

<a id="topic-1.1.1-1"></a>

### Summary: definition and prevalence

Obstructive sleep apnea (OSA) is upper airway collapse during sleep that partially or completely interrupts airflow through apneas and hypopneas. The VA/DoD 2025 guideline grades severity by events per hour: mild at 5 to fewer than 15 with symptoms, moderate at 15 to fewer than 30, and severe at 30 or more. Prevalence increases with age, body mass index, and male sex (2:1), and the risk in women increases after menopause. The apnea-hypopnea index (AHI) of one person can differ considerably depending on which hypopnea definition is used, so each prevalence figure below keeps its scoring rule and age band.

- 2007 to 2010, hypopneas scored with 4% desaturation, adults aged 30 to 70: 26% (95% CI 24 to 28) had AHI of 5 or more and 10% (95% CI 8 to 11) had AHI of 15 or more.
- Global and United States, AASM 2012 criteria, adults aged 30 to 69 (ResMed employees among the authors): 936 million adults worldwide had AHI of 5 or more and 425 million had AHI of 15 or more; in the United States, 54,131,654 of 163,246,772 adults aged 30 to 69 (33.2%) had AHI of 5 or more and 23,678,109 (14.5%) had AHI of 15 or more.
- United States, 2024, AHI4 (4% desaturation) of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection; Clarivate and Apnimed employees among the authors): 83.7 million adults, an overall prevalence of 32.4%, with severity 52% mild, 30% moderate, and 18% severe.
- The Apnimed prospectus states approximately 80 million people in the United States between the ages of 30 and 69, from a study Apnimed commissioned from Clarivate. The prospectus age band (30 to 69) and the published Clarivate and Apnimed estimate (83.7 million, aged 20 years and older) are reported as each source states them.
- A systematic review of 24 general-population studies reported prevalence ranging from 9% to 38% at AHI of 5 or more and from 6% to 17% at AHI of 15 or more.
- Underdiagnosis: in one population without obvious barriers to health care for sleep disorders, an estimated 93% of women and 82% of men with moderate to severe sleep apnea syndrome had not been clinically diagnosed. A 2016 Frost & Sullivan report estimated 29.4 million U.S. adults (12%) with OSA at AHI over 5, of whom 20% (5.9 million) had been diagnosed.
- Diagnosed prevalence in nationwide medical and prescription claims (Symphony Health; Jazz Pharmaceuticals-funded) increased 41% over the study period, from 2,429 to 3,420 per 100,000.

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf); [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/); [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/); [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/); [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Senaratna et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27568340/); [Young et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9406321/); [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf); [Acquavella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446073/)

<a id="topic-1.1.1-2"></a>

### Summary: natural history and long-term morbidity

- Progression: among 690 employed Wisconsin adults evaluated twice at 4-year intervals, a 10% weight gain predicted an approximate 32% (95% CI 20% to 45%) increase in AHI and a 6-fold (95% CI 2.2 to 17.0) increase in the odds of developing an AHI of 15 or more; a 10% weight loss predicted a 26% decrease. In 2968 participants, sleep-disordered breathing progressed over 5 years even in those with stable weight.
- Mortality: over 18 years in the Wisconsin Sleep Cohort (n = 1522; hypopneas with 4% desaturation), the adjusted hazard ratio for all-cause mortality with severe versus no sleep-disordered breathing was 3.0 (1.4 to 6.3), and 3.8 (1.6 to 9.0) after excluding 126 CPAP users, with a hazard ratio of 5.2 (1.4 to 19.2) for cardiovascular mortality. In 6,441 Sleep Heart Health Study participants (4% desaturation; mean follow-up 8.2 years), the fully adjusted hazard ratio was 1.46 (1.14 to 1.86) for severe disease (AHI of 30 or more), 1.17 (0.97 to 1.42) for moderate, and 0.93 (0.80 to 1.08) for mild. A review of 26 articles found evidence in men for an association with all-cause mortality and a composite cardiovascular outcome, with other associations uncertain.
- Cardiovascular and metabolic morbidity: an AHI of 15 or more at baseline was associated with an odds ratio of 2.89 (1.46 to 5.64) for hypertension 4 years later. In a cohort of 1927 men and 2495 women (4% desaturation; median follow-up 8.7 years), men aged 40 to 70 with AHI of 30 or more were 68% more likely to develop coronary heart disease than those with AHI below 5, and men with AHI of 30 or more were 58% more likely to develop heart failure. In a cohort of 5,422 participants followed for a median of 8.7 years, men in the highest obstructive AHI quartile had an adjusted hazard ratio of 2.86 (1.1 to 7.4) for ischemic stroke. A meta-analysis of six prospective cohorts (5953 participants) reported a relative risk of 1.63 (1.09 to 2.45) for type 2 diabetes with moderate to severe OSA. An American Heart Association statement reports OSA prevalence of 40% to 80% in hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.
- Other outcomes: the mean crash-rate ratio associated with OSA is likely to fall between 1.21 and 4.89, and a pooled analysis of 6 prospective studies found a risk ratio of 1.26 (1.05 to 1.50) for cognitive impairment with sleep-disordered breathing.

Source: [Peppard et al. (2000b)](https://pubmed.ncbi.nlm.nih.gov/11122588/); [Newman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16287771/); [Young et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2542952/); [Punjabi et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2722083/); [Kendzerska et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/23642349/); [Peppard et al. (2000a)](https://pubmed.ncbi.nlm.nih.gov/10805822/); [Gottlieb et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3117288/); [Redline et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2913239/); [Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22988888/); [Yeghiazarians et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34148375/); [Tregear et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792976/); [Leng et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710301/)

<a id="topic-1.1.1-3"></a>

### Summary: humanistic and economic burden

- Health-related quality of life: in 5,816 Sleep Heart Health Study participants, mild to moderate sleep-disordered breathing was associated with reduced SF-36 vitality and severe disease with poorer scores on several SF-36 scales. In a survey, respondents reporting an OSA diagnosis with excessive sleepiness (n = 731) had SF-6D utility of 0.65, against 0.69 for those without excessive sleepiness (n = 1,452) and 0.73 for controls without OSA (n = 86,961), and work impairment of 29.41%, 21.82%, and 16.85%, respectively.
- Health state utilities from a time trade-off vignette study of 208 participants in the United Kingdom and the United States ranged from 0.93 for mild to 0.85 for severe OSA when non-pharmacologic treatment was available, and from 0.89 to 0.68 without that option.
- Bed partners: most studies in a review found that untreated OSA impairs partners' sleep, daytime functioning, mood, quality of life, and relationship quality; in one study of 54 participants with OSA, bed partners' Epworth Sleepiness Scale score decreased from 7.4 to 5.8 after patient CPAP treatment.
- Societal cost: a Frost & Sullivan report estimated that undiagnosed OSA cost the United States approximately $149.6 billion in 2015; it also estimated $86.9 billion in lost productivity from untreated OSA and $26.2 billion as the total economic impact of motor vehicle accidents in which undiagnosed OSA was a contributing factor. A 2026 study using self-reported breathing pauses and excessive daytime sleepiness as a proxy estimated annual U.S. workplace productivity losses of US$180.2 billion.
- Health care costs: in Medicare beneficiaries (10,317 with OSA, 276,874 matched controls), mean total annual costs in the year before diagnosis were $19,566 (95% CI $13,239 to $25,894) higher, with inpatient care contributing the largest increment ($15,482). In one study, mean annual medical cost before diagnosis was $2720 for cases against $1384 for age- and gender-matched controls. Among 1,301 beneficiaries in a readmission analysis, high CPAP adherence was associated with lower odds of 30-day readmission than low adherence (odds ratio 0.41; 95% CI 0.24 to 0.70).

Source: [Baldwin et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11204058/); [Stepnowsky et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6374092/); [Stewart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41089051/); [Luyster et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337594/); [Parish and Lyng (2003)](https://pubmed.ncbi.nlm.nih.gov/12970021/); [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf); [Rehman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41735061/); [Wickwire et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7053009/); [Kapur et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10505820/); [Bailey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9713924/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
